Eupraxia Pharmaceuticals Q3 net loss more than doubles to $15.2 million
EPRX•Eupraxia Pharmaceuticals' third-quarter 2026 net loss more than doubled year over year to $15.2 million. It had $75.2 million in cash and cash equivalents and $51.2 million in short-term investments at September 30, and expects its cash reserves to fund operations into the second half of 2028.
1. Quarterly results
Eupraxia Pharmaceuticals' third-quarter 2026 net loss more than doubled year over year to $15.2 million. Cash and cash equivalents totaled $75.2 million at September 30, 2026, with short-term investments of $51.2 million.
2. Trial enrollment
The Phase 2b RESOLVE trial of EP-104GI reached its target enrollment of 120 patients. Interim results are expected in December 2026, and the company expects existing cash reserves to fund operations into the second half of 2028.
Related News
Big Sky Industrial Q3 revenue rises on higher prices
BSIN•
Annaly Capital announces fourth-quarter preferred dividends of $0.583074 for Series F, $0.543578 for Series G, $0.554688 for Series J
NLY•
